Consequently, DCK is associated with prolonged survival of patients after adjuvant gemcitabine therapy for resected pancreatic ductal adenocarcinoma (PDAC) [18], and downregulation of DCK in vitro enhances resistance against gemcitabine in pancreatic tumor cells [19]. This evidence concerns the gene DCK and pancreatic neoplasm.